Is anti-seizure medication the culprit of SUDEP?
Issued Date
2023-01-01
Resource Type
ISSN
15901874
eISSN
15903478
Scopus ID
2-s2.0-85160417433
Journal Title
Neurological Sciences
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neurological Sciences (2023)
Suggested Citation
Leosuthamas D., Limotai C., Unwanatham N., Rattanasiri S. Is anti-seizure medication the culprit of SUDEP?. Neurological Sciences (2023). doi:10.1007/s10072-023-06871-0 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82975
Title
Is anti-seizure medication the culprit of SUDEP?
Author(s)
Other Contributor(s)
Abstract
Background: Heart rate variability (HRV) reduction is a potential biomarker for sudden cardiac death. This study aimed to study the effects of anti-seizure medications (ASMs), adjusted with reported factors associated with sudden unexpected death in epilepsy (SUDEP) on HRV parameters. Methods: We recruited patients who were admitted in our epilepsy monitoring unit between January 2013 and December 2021. Two 5-min electrocardiogram epochs during wakefulness and sleep were selected in each patient. HRV analysis with Python® software was performed. The imputed datasets were used for linear regression analysis to assess association between each ASM item and all HRV parameters. The effects of ASM on HRV parameters were subsequently adjusted with the significant clinical characteristics and the concomitant use of other ASMs, respectively. Results: Carbamazepine (CBZ), levetiracetam (LEV), lamotrigine (LTG), and clonazepam (CZP) were statistically significantly associated with changes of sleep HRV parameters. Only CBZ showed negative effects with reduction in HRV, evidenced as lower standard deviation of RR interval (SDNN), even when adjusted with concomitant use of other ASMs (p = 0.045) and had a trend of significance when adjusted with significant clinical characteristics of concurrent taking of beta-blocker drug (p = 0.052). LEV and CZP showed opposite effects with increased HRV even when adjusted with significant clinical characteristics and the concomitant use of other ASMs. Conclusions: CBZ showed negative effects on HRV. We proposed that CBZ should be cautiously used in patients with known risks for SUDEP. In addition, HRV assessment should be performed prior to commencing CBZ and re-performed in follow-up in cases of prolonged use.